Familial ALS and Scribe CRISPR Conversation

Join the Familial ALS Community Team and Scribe CRISPR on Tuesday, January 18 at 12:00 p.m. ET for a conversation about applying CRISPR gene-editing technology to ALS from Brett Staahl, PhD, co-founder and VP of Platform Technologies at Scribe Therapeutics.

CRISPR is a gene-editing technique that allows researchers to edit parts of the genome by adding, removing or changing specific sections of DNA.



Take Action

Back to Top